Roivant Sciences Officer Exercises Options and Sells $7.15M in Common Shares Under 10b5-1 Plan

Insider Transaction Overview

On August 28, 2026, Eric Venker, President of Roivant Sciences Ltd. and CEO of Immunovant, executed an option exercise and sale transaction:

• Option Exercise: Exercised options to purchase 200,000 Common Shares at a strike price of $3.85 per share.
• Open Market Sales: Sold all 200,000 shares in two tranches under a pre-established Rule 10b5-1 trading plan:
  • 166,182 shares at a weighted average price of $35.63 ($35.17 – $36.16)
  • 33,818 shares at a weighted average price of $36.44 ($36.17 – $36.80)
• Gross Sale Value: $7,153,392.58
• Net Cash Generated: ~$6,383,392.58 (after deducting the $770,000 exercise cost).

Holdings Context & Plan Details

• 10b5-1 Trading Plan: The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
• Remaining Holdings: Following the transaction, Dr. Venker continues to hold 1,599,154 directly owned common shares and 3,844,834 stock options.